Last reviewed · How we verify
Continuous infusion of Norepinephrine
Norepinephrine is a catecholamine that binds to alpha and beta adrenergic receptors to increase heart rate, cardiac contractility, and peripheral vasoconstriction, thereby raising blood pressure and improving tissue perfusion.
Norepinephrine is a catecholamine that binds to alpha and beta adrenergic receptors to increase heart rate, cardiac contractility, and peripheral vasoconstriction, thereby raising blood pressure and improving tissue perfusion. Used for Acute hypotension and shock (septic shock, cardiogenic shock, anaphylactic shock), Maintenance of blood pressure during anesthesia, Acute decompensated heart failure with hypotension.
At a glance
| Generic name | Continuous infusion of Norepinephrine |
|---|---|
| Sponsor | Hassan II University |
| Drug class | Catecholamine; sympathomimetic amine |
| Target | Alpha-1 adrenergic receptor; Beta-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular; Critical Care |
| Phase | FDA-approved |
Mechanism of action
Norepinephrine acts as both a neurotransmitter and sympathomimetic agent, stimulating alpha-1 adrenergic receptors on vascular smooth muscle to cause vasoconstriction and beta-1 adrenergic receptors on the heart to increase contractility and heart rate. When administered as a continuous IV infusion, it rapidly restores blood pressure and organ perfusion in hypotensive states by increasing systemic vascular resistance and cardiac output.
Approved indications
- Acute hypotension and shock (septic shock, cardiogenic shock, anaphylactic shock)
- Maintenance of blood pressure during anesthesia
- Acute decompensated heart failure with hypotension
Common side effects
- Hypertension
- Tachycardia
- Arrhythmias
- Headache
- Anxiety
- Tissue necrosis at infusion site (extravasation)
- Peripheral vasoconstriction and ischemia
Key clinical trials
- Angiotensin II in Liver Transplantation (PHASE2, PHASE3)
- Dysfunctional Renin-Angiotensin System in Septic Shock (PHASE4)
- Comparison of Plasma Neutrophil Gelatinase-Associated Lipocalin (pNGAL) Level in De-resuscitation With Furosemide Group and Control Group (NA)
- Low-dose Arginine-vasopressin Supplementation on Post-transplant Acute Kidney Injury After Liver Transplantation (AVENIR Trial) (PHASE3)
- Methylene Blue for the Treatment of Septic Shock (PHASE3)
- Maximising Time With a Normal Blood Glucose to Restore the Glucagon Response in Type 1 Diabetes (NA)
- Comparison of the Efficacy of Continuous Metaraminol Infusion Versus Continuous Norepinephrine Infusion for the Prevention of Hypotension During Cesarean Section Under Spinal Anaesthesia. A Randomised Controlled Trial. (NA)
- Norepinephrine vs. Phenylephrine for Hypotension in Low-Dose Spinal Anesthesia for Cesarean Delivery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Continuous infusion of Norepinephrine CI brief — competitive landscape report
- Continuous infusion of Norepinephrine updates RSS · CI watch RSS
- Hassan II University portfolio CI